With an estimated 6.9 million Americans aged 65 and older currently living with Alzheimer’s disease, the road to a cure seems ...

Alzheimer's disease begins with a long period during which abnormal amyloid and tau proteins build up in the brain without ...

The treatment is not a permanent fix for Alzheimer's dementia, Jing said, because the disease will eventually ... It's important for them to know there are options out there." ...

The Alzheimer’s disease market is expected to grow at a CAGR of 23.4% from $2.4bn in 2023 to $19.3bn by 2033 across the 8MM ...

A groundbreaking discovery by scientists at Japan’s RIKEN Center for Brain Science has revealed an unexpected link between dopamine and Alzheimer’s disease ... s treatment stems from its ...

"These findings reveal a critical link between cellular stress and the neurotoxic effects of microglia in Alzheimer's disease." "Targeting this pathway may open up new avenues for treatment by ...

MINNEAPOLIS — A drug approved by the FDA over the summer is giving new hope to the nearly 7 million Americans suffering from Alzheimer's disease. The drug, sold under the brand name Kisunla and ...

Blarcamesine is an orally once daily administered small molecule for the potential treatment of patients with Alzheimer’s disease. “The EMA filing acceptance for blarcamesine to review the ...

Former study was recently accepted in a peer-reviewed medical journal with focus on Alzheimer’s disease titled, “Blarcamesine for the treatment of Early Alzheimer’s Disease: Results from the ...

"We're excited about the chance to have researchers test our findings in ways that make a difference in the study, subtyping, treatment and prevention of Alzheimer's disease." The findings of the ...

For decades, scientists have been trying to develop therapeutics for people living with Alzheimer’s disease, a progressive ...